Chief Executive Officer
Karl has over 25 years’ experience in the pharmaceutical industry, beginning his career at BASF in the chemicals business with roles in operations and commercial, including sales and marketing and leading manufacturing sites.
Following his time at BASF, Karl joined Royal DSM as Director of Business Projects, progressing to Business Unit Director in the CDMO division in Austria. He then led the Anti-Infectives business, a global manufacturer of enzymatic APIs, specifically antibiotics at DSM. Here he was instrumental in the establishment of a joint venture with Sinochem, called DSM Sinochem Pharmaceuticals based out of Singapore.
Karl went on to become CEO at Centrient Pharmaceuticals, when the DSM/Sinochem joint venture became private equity owned.
More recently, Karl held the position of CEO at EuroAPI, a CDMO specialised in developing and manufacturing APIs with significant expertise in high potency, peptides, toxin linkers and oligonucleotides which he brought to the stock market at Euronext Paris as carve out from Sanofi.
Related
Facilities
